Lupin tops world pharma and all Indian sectors in S&P ESG rankings

Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally

Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer

KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients

FDA nod to Boehringer Ingelheim’s first-line therapy for HER2-mutant lung cancer

Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy

Starton Therapeutics doses first patient in Phase 2a trial of STAR-LLD for multiple myeloma

The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.

Bayer introduces chemo-free treatment option for advanced prostate cancer in India

Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years

Lupin receives European Commission approval for biosimilar Ranibizumab

Lonza scales bioconjugate innovation through enhanced synthesis offering

Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization

Novartis bags Phase III win for Remibrutinib in chronic inducible urticaria

The results mark a potential breakthrough for patients living with CIndU, a condition with limited treatment options

GSK announces breakthrough data showing RSV vaccine cuts hospitalizations in elderly

The data highlights its RSV vaccine cuts hospitalizations in older adults